Grace Therapeutics, Inc.
Financial highlights
| Metric | FY March 31, 2025 | FY March 31, 2024 | FY March 31, 2023 | FY March 31, 2022 | FY March 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $196,000 |
| Operating income | -$16.7M | -$12.9M | -$52.2M | -$15.6M | -$16.4M |
| Cost of revenue | — | — | — | $0 | $76,000 |
| Cash from operations | -$14.9M | -$12.3M | -$15.9M | -$17.2M | -$14.3M |
| Impairments | $0 | $0 | $28.7M | $0 | $1.6M |
| Total assets | $72.0M | $73.3M | $79.1M | $128.6M | $62.5M |
| Total liabilities | $5.4M | $11.6M | $11.2M | $20.4M | $6.8M |
Shares outstanding 15.5M
Annual filing data through FY ended March 31, 2025; float as of July 4, 2026.